Aveo Pharmaceuticals, Inc. (AVEO) SEC Filing 8-K Material Event for the period ending Monday, November 29, 2021

Aveo Pharmaceuticals Inc

CIK: 1325879 Ticker: AVEO

View differences made from one to another to evaluate Aveo Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aveo Pharmaceuticals Inc.


Assess how Aveo Pharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aveo Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Ticker: AVEO
CIK: 1325879
Form Type: 8-K Corporate News
Accession Number: 0001628280-21-024277
Submitted to the SEC: Wed Dec 01 2021 7:00:49 AM EST
Accepted by the SEC: Wed Dec 01 2021
Period: Monday, November 29, 2021
Industry: Pharmaceutical Preparations
  1. Event for Officers

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: